|Awarded On||August 21, 2019|
|Title||Nanosized immunotherapies to access and treat pediatric medulloblastoma|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Jennifer Maynard|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor in children with no long-term cure. Current therapies rely on radiation which provides only a brief respite from disease. Even when temporarily successful, the therapies themselves cause significant damage to healthy brain tissue. A significant unmet need is development of effective therapies that can be delivered non-invasively, are non-toxic for non-tumor tissues and do not cause inflammation within the central nervous system. We aim to generate a multi-functional antibody able to penetrate the blood-brain barrier and starve DIPG cells of essential nutrients. Cancer cells are notable for their rapid growth, which must...